Optimization of fed-batch parameters and harvest time of CHO cell cultures for a glycosylated product with multiple mechanisms of inactivation

Biotechnology and Bioengineering

Volumn 98, Issue 2, 2007, Pages 378-390

  Senger, Ryan S ^a   Karim, M Nazmul ^b  

^a Northwestern University   (United States)

^b Department of Electrical and Computer Engineering   (United States)

Author keywords

Enzyme inactivation; Fed batch; Glycation; Glycosylation; Optimization; Tissue plsminogen activator

Indexed keywords

AMINO ACIDS; COMPUTER SIMULATION; GLUCOSE; GLYCOSYLATION; OPTIMIZATION; PROTEINS;

ENZYME INACTIVATION; GROWTH PHASE; INACTIVATION; TISSUE PLSMINOGEN ACTIVATOR;

CELL CULTURE;

ALTEPLASE; AMINO ACID; ASPARAGINE; GLUCOSE; GLUTAMINE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; ENZYME INACTIVATION; FED BATCH CULTURE; GLYCOSYLATION; MOLECULAR DYNAMICS; NONHUMAN; REACTION OPTIMIZATION; SIMULATION; SUPERNATANT;

AMINO ACIDS; ANIMALS; BIOREACTORS; CHEMISTRY, PHARMACEUTICAL; CHO CELLS; CRICETINAE; CRICETULUS; DRUG INDUSTRY; GLUCOSE; GLYCOSYLATION; KINETICS; RECOMBINANT PROTEINS; TISSUE CULTURE TECHNIQUES; TISSUE PLASMINOGEN ACTIVATOR;

EID: 34948817299     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.21428     Document Type: Article

References (40)

1. Andersen DC, Bridges T, Gawlitzek M, Hoy C. 2000. Multiple cell culture factors can affect the glycosyiation of Asn-184 in CHO-produced tissue-type plasminogen activator. Biotechnol Bioeng 70(1):25-31.
2. Baki A, Tompa P, Alexa A, Molnar O, Friedrich P. 1996. Autolysis parallels activation of mu-calpain. Biochem J 318(Pt 3):897-901.
3. Bruins ME, Van Hellemond EW, Janssen AE, Boom RM. 2003. Maillard reactions and increased enzyme inactivation during oligosaccharide synthesis by a hyperthermophilic glycosidase. Biotechnol Bioeng 81(5):546-552.
4. Brunk CF, Jones KC, James TW. 1979. Assay for nanogram quantities of DNA in cellular homogenates. Anal Biochem 92(2):497-500.
5. Bunn HF, Forget BG. 1993. Hemoglobin: Molecular, genetic and clinical aspects. Philadelphia: W.B. Sanders.
6. Byrn SR, Xu W, Newman AW. 2001. Chemical reactivity in solid-state pharmaceuticals: Formulation implications. Adv Drug Deliv Rev 48(1):115-136.
7. Cumming DA. 1991. Glycosylation of recombinant protein therapeutics: Control and functional implications. Glycobiology 1(2):115-130.
8. Dworschak E. 1980. Nonenzyme browning and its effect on protein nutrition. Crit Rev Food Sci Nutr 13(1):1-40.
9. Ellis GP. 1959. The Maillard reaction. Adv Carbohydr Chem 14:63-134.
10. Goochee CF, Monica T. 1990. Environmental effects on protein glycosylation. Biotechnology (NY) 8(5):421-427.
11. Grossbard EB. 1987. Recombinant tissue plasminogen activator: A brief review. Pharm Res 4(5):375-378.
12. Hayase F, Nagaraj RH, Miyata S, Njoroge FG, Monnier VM. 1989. Aging of proteins: Immunological detection of a glucose-derived pyrrole formed during maillard reaction in vivo. J Biol Chem 264(7):3758-3764.
13. Kapadi MD, Gudi RD. 2004. Optimal control of fed-batch fermentation involving multiple feeds using differential evolution. Process Biochem 39(11):1709-1721.
14. Kendrick BS, Cleland JL, Lam X, Nguyen T, Randolph TW, Manning MC, Carpenter JF. 1998. Aggregation of recombinant human interferon gamma: Kinetics and structural transitions. J Pharm Sci 87(9):1069-1076.
15. Kookos IK. 2004. Optimization of batch and fed-batch bioreactors using simulated annealing. Biotechnol Prog 20(4):1285-1288.
16. Lang IM, Schleef RR. 1996. Calcium-dependent stabilization of type I plasminogen activator inhibitor within platelet alpha-granules. J Biol Chem 271(5):2754-2761.
17. Lijnen HR, Collen D. 1987. Tissue-type plasminogen activator. Ann Biol Clin (Paris) 45(2):198-201.
18. Lubbert A, Bay Jorgensen S. 2001. Bioreactor performance: A more scientific approach for practice. J Biotechnol 85(2):187-212.
19. Mahadevan R, Doyle IF. 2003. On-line optimization of recombinant product in a fed-batch bioreactor. Biotechnol Prog 19(2):639-646.
20. Nagaraj RH, Monnier VM. 1995. Protein modification by the degradation products of ascorbate: Formation of a novel pyrrole from the Maillard reaction of L-threose with proteins. Biochim Biophys Acta 1253(1):75-84.
21. Parekh RB, Dwek RA, Thomas JR, Opdenakker G, Rademacher TW, Wittwer AJ, Howard SC, Nelson R, Siegel NR, Jennings MG, et al. 1989. Cell-type-specific and site-specific N-glycosylation of type I and type II human tissue plasminogen activator. Biochemistry 28(19):7644-7662.
22. Rani KY, Rao VSR. 1999. Control of fermenters: A review. Bioprocess Eng 21(1):77-88.
23. Rijken DC, Collen D. 1981. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 256(13):7035-7041.
24. Roberts CJ, Darrington RT, Whitley MB. 2003. Irreversible aggregation of recombinant bovine granulocyte-colony stimulating factor (bG-CSF) and implications for predicting protein shelf life. J Pharm Sci 92(5):1095-1111.
25. Saido TC, Nagao S, Shiramine M, Tsukaguchi M, Yoshizawa T, Sorimachi H, Ito H, Tsuchiya T, Kawashima S, Suzuki K. 1994. Distinct kinetics of subunit autolysis in mammalian m-calpain activation. FEBS Lett 346(2-3):263-267.
26. Sarkar D, Modak JM. 2004. Genetic algorithms with filters for optimal control problems in fed-batch bioreactors. Bioprocess Biosyst Eng 26(5):295-306.
27. Senger RS. 2005. Modeling recombinant enzyme inactivation and prediction of N-linked glycosyiation site-occupancy and microheterogeneity. Thesis. Fort Collins: Colorado State University.
28. Senger RS, Karim MN. 2003a. Effect of shear stress on intrinsic CHO culture state and glycosyiation of recombinant tissue-type plasminogen activator protein. Biotechnol Prog 19(4):1199-1209.
29. Senger RS, Karim MN. 2003b. Neural-network-based identification of tissue-type plasminogen activator protein production and glycosylation in CHO cell culture under shear environment. Biotechnol Prog 19(6):1828-1836.
30. Shapiro R, McManus MJ, Zalut C, Bunn HF. 1980. Sites of nonenzymatic glycosyiation of human hemoglobin A. J Biol Chem 255(7):3120-3127.
31. Shiraki K, Kudou M, Nishikori S, Kitagawa H, Imanaka T, Takagi M. 2004. Arginine ethylester prevents thermal inactivation and aggregation of lysozyme. Eur J Biochem 271(15):3242-3247.
32. Simon L, Karim MN. 2002. Control of starvation-induced apoptosis in Chinese hamster ovary cell cultures. Biotechnol Bioeng 78(6):645-657.
33. Skolpap W, Scharer JM, Douglas PL, Moo-Young M. 2004. Fed-batch optimization of alpha-amylase and protease-producing Bacillus subtilis using Markov chain methods. Biotechnol Bioeng 86(6):706-717.
34. Spellman MW, Basa LJ, Leonard CK, Chakel JA, O'Connor JV, Wilson S, van Halbeek H. 1989. Carbohydrate structures of human tissue plasminogen activator expressed in Chinese hamster ovary cells. J Biol Chem 264(24):14100-14111.
35. Stevens WK, Cote HF, MacGillivray RT, Nesheim ME. 1996. Calcium ion modulation of meizothrombin autolysis at Arg55-Asp56 and catalytic activity. J Biol Chem 271(14):8062-8067.
36. Stoll T, Pugeaud P, von Stockar U, Marison IW. 1994. A simple HPLC technique for accurate monitoring of mammalian cell metabolism. Cytotechnology 14(2):123-128.
37. Wang W, Kelner DN. 2003. Correlation of rFVIII inactivation with aggregation in solution. Pharm Res 20(4):693-700.
38. Wittwer AJ, Howard SC. 1990. Glycosyiation at Asn-184 inhibits the conversion of single-chain to two-chain tissue-type plasminogen activator by plasmin. Biochemistry 29(17):4175-4180.
39. Wittwer AJ, Howard SC, Carr LS, Harakas NK, Feder J, Parekh RB, Rudd PM, Dwek RA, Rademacher TW. 1989. Effects of N-glycosylation on in vitro activity of Bowes melanoma and human colon fibroblast derived tissue plasminogen activator. Biochemistry 28(19):7662-7669.
40. Xu Y, Cacia J. 2000. A reversed-phase HPLC assay for plasminogen activators. J Liq Chromatogr R T 23(12):1841-1850.